share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

诺和诺德 | 6-K:诺和诺德-股票回购计划
美股SEC公告 ·  06/03 11:05
Moomoo AI 已提取核心信息
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on May 6, 2024, as part of a larger 12-month buyback plan worth up to DKK 20 billion, which began on February 6, 2024. From May 7 to August 5, 2024, Novo Nordisk is set to repurchase B shares for up to DKK 2.2 billion. As of May 31, 2024, the company has repurchased 9,366,795 B shares at an average price of DKK 865.36, totaling DKK 8,105,649,158. The recent transactions from May 27 to May 31, 2024, resulted in the acquisition of 196,393 B shares for a combined value of DKK 180,735,500, bringing the total shares repurchased under the program to 632,545. Novo Nordisk now holds 10,732,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program. The company, headquartered in Denmark, initiated this program on May 6, 2024, as part of a larger 12-month buyback plan worth up to DKK 20 billion, which began on February 6, 2024. From May 7 to August 5, 2024, Novo Nordisk is set to repurchase B shares for up to DKK 2.2 billion. As of May 31, 2024, the company has repurchased 9,366,795 B shares at an average price of DKK 865.36, totaling DKK 8,105,649,158. The recent transactions from May 27 to May 31, 2024, resulted in the acquisition of 196,393 B shares for a combined value of DKK 180,735,500, bringing the total shares repurchased under the program to 632,545. Novo Nordisk now holds 10,732,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.
领先的全球医疗保健公司Novo Nordisk A/S已经报告了其股票回购计划的进展情况。该公司总部位于丹麦,于2024年2月6日启动了为期12个月,价值高达200亿丹麦克朗的更大规模的回购计划,并于2024年5月6日启动了这项计划。从2024年5月7日到8月5日,Novo Nordisk计划回购B类股票,总价值高达22亿丹麦克朗。截至2024年5月31日,该公司已回购9366795股B类股票,平均价值为865.36丹麦克朗,共计8105649158丹麦克朗。2024年5月27日至5月31日的最近交易导致获得196393股B类股票,合计价值为180735500丹麦克朗,使得该计划下回购的股票总数达到632545股。Novo Nordisk现持有10732359股B类股票作为库存股份,占股本的0.2%。该公司的股票在纳斯达克哥本哈根和纽约证券交易所上市。
领先的全球医疗保健公司Novo Nordisk A/S已经报告了其股票回购计划的进展情况。该公司总部位于丹麦,于2024年2月6日启动了为期12个月,价值高达200亿丹麦克朗的更大规模的回购计划,并于2024年5月6日启动了这项计划。从2024年5月7日到8月5日,Novo Nordisk计划回购B类股票,总价值高达22亿丹麦克朗。截至2024年5月31日,该公司已回购9366795股B类股票,平均价值为865.36丹麦克朗,共计8105649158丹麦克朗。2024年5月27日至5月31日的最近交易导致获得196393股B类股票,合计价值为180735500丹麦克朗,使得该计划下回购的股票总数达到632545股。Novo Nordisk现持有10732359股B类股票作为库存股份,占股本的0.2%。该公司的股票在纳斯达克哥本哈根和纽约证券交易所上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息